Compare Stocks → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EPZMOTCMKTS:INVVYNASDAQ:STOKNASDAQ:TOCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsSTOKStoke Therapeutics$14.17+37.7%$5.88$3.35▼$16.40$476.47M0.681.41 million shs17.72 million shsTOCATocagen$0.69-1.4%$32.24$0.42▼$6.77$16.62M0.011.47 million shs15,008 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%+9.12%STOKStoke Therapeutics+37.71%+136.56%+113.08%+162.41%+76.46%TOCATocagen-2.13%-0.64%+0.56%-4.94%-29.49%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/ASTOKStoke Therapeutics4.6318 of 5 stars4.43.00.04.83.11.70.0TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPZMEpizymeN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/ASTOKStoke Therapeutics2.78Moderate Buy$19.6338.50% UpsideTOCATocagenN/AN/AN/AN/ACurrent Analyst RatingsLatest EPZM, TOCA, INVVY, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $17.003/26/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.003/26/2024STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/26/2024STOKStoke TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/26/2024STOKStoke TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $13.003/26/2024STOKStoke TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.002/16/2024STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07STOKStoke Therapeutics$8.78M74.72N/AN/A$4.69 per share3.02TOCATocagen$40K415.53N/AN/A$0.45 per share1.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/ASTOKStoke Therapeutics-$101.07M-$2.37N/AN/AN/AN/A-56.86%-41.59%5/2/2024 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPZMEpizymeN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPZMEpizymeN/A5.355.19INVVYIndiviorN/AN/AN/ASTOKStoke TherapeuticsN/A6.999.13TOCATocagen1.881.151.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPZMEpizyme76.45%INVVYIndivior0.05%STOKStoke TherapeuticsN/ATOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipEPZMEpizyme23.40%INVVYIndiviorN/ASTOKStoke Therapeutics12.30%TOCATocagen10.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEPZMEpizyme250168.33 million128.97 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionableSTOKStoke Therapeutics11746.30 million39.16 millionOptionableTOCATocagen7723.92 millionN/ANot OptionableEPZM, TOCA, INVVY, and STOK HeadlinesSourceHeadlineGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizpharmiweb.com - March 25 at 4:25 AMONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Gliomaascopubs.org - February 12 at 6:14 PMMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorseurekalert.org - January 20 at 12:14 AMForte Biosciences: Changes In Registrant S Certifying Accountantcbonds.com - December 12 at 8:27 AMRiskOn International And 3 Other Stocks Under $2 Insiders Are Buyingmarkets.businessinsider.com - December 11 at 9:20 AMPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedpharmaceutical-technology.com - November 6 at 9:33 AMProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointmentfinance.yahoo.com - November 2 at 10:33 AMFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma Patientsprecisionmedicineonline.com - July 26 at 11:09 PMGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRnews.google.com - May 12 at 8:33 AMForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comnews.google.com - April 29 at 12:45 AMGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comnews.google.com - April 6 at 8:25 PMBelzutifan plus cabozantinib for patients with advanced clear cell ... - The Lancetnews.google.com - March 31 at 11:10 PMCurrent drug development and trial designs in neuro-oncology ... - The Lancetnews.google.com - March 28 at 12:07 AMCompanion Diagnostics Market is set to experience a significant ... - Digital Journalnews.google.com - March 27 at 8:37 AMOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital Journalnews.google.com - March 14 at 4:44 PMAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital Journalnews.google.com - March 8 at 10:39 AMAnaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan Newsnews.google.com - March 2 at 1:05 PMAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029marketwatch.com - February 28 at 3:22 AMCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029marketwatch.com - February 27 at 9:31 AMAn echo through brain cancer’s empty pipelinepharmaphorum.com - February 7 at 7:04 PMCompanion Diagnostics Market Size, Share, Growth Statistics By ... - Digital Journalnews.google.com - February 3 at 6:12 AMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo Financenews.google.com - February 2 at 1:10 PMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR Newswirenews.google.com - February 2 at 8:09 AMHuman Resource Management Market Booming Worldwide With ... - Rejoice Magazinenews.google.com - January 27 at 11:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEpizymeNASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Stoke TherapeuticsNASDAQ:STOKStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.